venclexta 100mg tableta recubierta
abbvie sas, sucursal del peru - droguerÍa - venetoclax; - tableta recubierta - por tableta - - venetoclax
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocítica, crónica, b-cell - agentes antineoplásicos - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
venclexta 50mg tableta recubierta
abbvie sas, sucursal del peru - tableta recubierta - por tableta - venetoclax
venclexta 10mg, 50mg,100mg tableta recubierta
abbvie sas, sucursal del peru - tableta recubierta - por tableta - venetoclax
venclexta 10mg tableta recubierta
abbvie sas, sucursal del peru - tableta recubierta - por tableta - venetoclax
venclexta 100 mg comprimido recubierto
abbvie - comprimido recubierto - venetoclax 100 mg comprimido
venclexta 10 mg comprimido recubierto
abbvie - comprimido recubierto - venetoclax 10 mg comprimido
venclexta 50 mg comprimido recubierto
abbvie - comprimido recubierto - venetoclax 50 mg comprimido
venclexta polvo liofilizado para solución inyectable
abbvie - polvo liofilizado para solución inyectable - venetoclax 10 mg comprimido y venetoclax 50 mg comprimido y venetoclax 100 mg comprimido y venetoclax 100 mg comprimido
venclexta 100 mg tabletas recubiertas
abbvie inc. estados unidos - cada tableta recubierta contiene: venetoclax 100.0 mg - tableta recubierta - cada tableta recubierta contiene: venetoclax 100.0 mg